Syros to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.

Piper Sandler 33rd Annual Healthcare Conference
Date: Tuesday, November 23, 2021
Presentation Time: A pre-recorded fireside chat will be made available on-demand beginning at 10:00 a.m. ET

JMP Securities Hematology and Oncology Summit
Date: Monday, December 6, 2021
Presentation Time: 10:40 a.m. ET

To access the webcasts and subsequent archived recording of each fireside chat, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005077/en/

Media Contact:
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
[email protected]

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Source: Syros Pharmaceuticals

You May Also Be Interested In

• GreenFirst Reports Financial Results for the Second Quarter of 2026 and CEO Transition Plan
• Sirion Completes IRAP Assessment at OFFICIAL: Sensitive Level in Australia
• Beanstalk AgTech Announces the Launch of Monsoon Ventures to Accelerate Agtech Commercialisation in Southeast Asia